 Antigen-binding fragment of durvalumab (pale green) in complex with PD-L1 (pink). PDB: 5X8M. | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD274 |
| Clinical data | |
| Trade names | Imfinzi |
| Other names | MEDI4736, MEDI-4736 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617030 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6502H10018N1742O2024S42 |
| Molar mass | 146322.36 g·mol−1 |
Durvalumab,[8] sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca.[9] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).[medical citation needed]
Durvalumab is an immune checkpoint inhibitor drug.[10] It was approved in for medical use in the United States in May 2017,[6][9][11][12] and in the European Union in September 2018.[7]
- ^ "Durvalumab (Imfinzi) Use During Pregnancy". Drugs.com. 30 August 2019. Archived from the original on 29 August 2021. Retrieved 7 February 2020.
- ^ "Imfinzi (AstraZeneca Pty Ltd)". Therapeutic Goods Administration (TGA). 5 December 2022. Archived from the original on 18 March 2023. Retrieved 9 April 2023.
- ^ "Auspar: Imfinzi". 8 December 2023. Retrieved 18 June 2024.
- ^ "Regulatory Decision Summary - Imfinzi". Health Canada. 23 October 2014. Archived from the original on 7 June 2022. Retrieved 6 September 2022.
- ^ "Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.
- ^ a b Cite error: The named reference
Imfinzi FDA labelwas invoked but never defined (see the help page). - ^ a b "Imfinzi EPAR". European Medicines Agency (EMA). 30 October 2018. Archived from the original on 28 August 2021. Retrieved 30 September 2020.
- ^ World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 74". WHO Drug Information. 29 (3). hdl:10665/331070.
- ^ a b "Durvalumab (Imfinzi)". U.S. Food and Drug Administration (FDA). Archived from the original on 8 May 2017. Retrieved 6 May 2017.
- ^ Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet. Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.
- ^ "FDA approves durvalumab for extensive-stage small cell lung cancer". U.S. Food and Drug Administration (FDA). 27 March 2020. Retrieved 19 July 2024.
- ^ Mathieu L, Shah S, Pai-Scherf L, Larkins E, Vallejo J, Li X, et al. (May 2021). "FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer". The Oncologist. 26 (5): 433–438. doi:10.1002/onco.13752. PMC 8100557. PMID 33687763.